188
Participants
Start Date
October 3, 2022
Primary Completion Date
June 30, 2027
Study Completion Date
October 30, 2027
Cladribine Subcutaneous Injection
Cladribine subcutaneous injection, 10 mg daily, for 2-3 consecutive days (depending on individual dose)
0.9% Chloride Injection Sodium
0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
RECRUITING
Institute of Psychiatry and Neurology, Warsaw
Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
OTHER
Mossakowski Medical Research Centre Polish Academy of Sciences
OTHER
Poznan University of Medical Sciences
OTHER
Military Institute of Aviation Medicine
OTHER_GOV
Institute of Psychiatry and Neurology, Warsaw
OTHER